---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: FORTIFI-HN01"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: FORTIFI-HN01. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 59 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence/fortifi-hn01"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: FORTIFI-HN01

<a id="heading-3.1.1"></a>

## 3.1.1 FORTIFI-HN01

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Study purpose in the ClinicalTrials.gov record

> “This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).”
> “The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.1-2"></a>

#### Phase 2 and phase 3 objectives in the EU trial record

> “Assessing safety and tolerability of ficerafusp alfa in participants randomized to ficerafusp alfa 1500 mg once weekly (QW) with pembrolizumab (Treatment Arm A) and ficerafusp alfa 750 mg QW with pembrolizumab (Treatment Arm B).”
> “Assessing antitumor activity of ficerafusp alfa in participants randomized to ficerafusp alfa 1500 mg QW with pembrolizumab (Treatment Arm A) and ficerafusp alfa 750 mg QW and pembrolizumab (Treatment Arm B).”
> “To compare efficacy in participants treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo plus pembrolizumab.”
> “Phase 3 secondary: To compare safety and tolerability of participants treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo plus pembrolizumab.”
> “Phase 3 secondary: To evaluate time to deterioration (TTD) in global health status/quality of life and pain in participants treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.1-3"></a>

#### Study question in the updated trial-in-progress poster

> “FORTIFI-HN01 (NCT06788990) is a Phase 2/3 study designed to investigate whether first-line (1L) treatment with ficerafusp alfa plus pembrolizumab improves objective response rate (ORR) and OS vs pembrolizumab alone in patients with HPV-negative, PD-L1–positive, R/M HNSCC”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates and sites in the ClinicalTrials.gov record

| Study characteristic | Quoted record |
| --- | --- |
| Study start (actual) | “2025-01-28” |
| Primary completion (estimated) | “2028-04” |
| Study completion (estimated) | “2029-07” |
| Sites | “This study has 231 locations” |

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.2-2"></a>

#### Enrollment regions in the updated trial-in-progress poster

> “FORTIFI-HN01 is open to enrollment at sites in North America, South America, Europe, Asia, and Oceania”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-3.1.1.2-3"></a>

#### First enrollment in the annual report

> “We enrolled the first patients in the FORTIFI-HN01 trial in February 2025.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Seamless phase 2 and phase 3 design in the ClinicalTrials.gov record

> “A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma”
> “Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:”
> “Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.3-2"></a>

#### Blinding in the EU trial record

> “Treatment will be blinded to subjects, investigator staff, persons performing the assessments, and the clinical study team.”
> “Once the OBD is determined, additional subjects will be randomized 2:1 in the treatment versus control arm.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.3-3"></a>

#### Stratification factors in the updated trial-in-progress abstract

> “Following OBD determination (1500 mg QW), the trial transitioned seamlessly into the phase 3 portion with 2:1 randomization (ficerafusp alfa:control).”
> “Randomization is stratified by PD-L1 CPS (1-19 vs ≥20) and disease extent (local/regional recurrence only, distant metastasis only, or both).”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.3-4"></a>

#### Phase 2 dose decision rule in the initial trial-in-progress poster

> “Phase 2: OBD decision”
> “After 10-20 patients per arm have ≥12 weeks of follow-up”

Source: [Ferrarotto et al. (2025b)](https://www.bicara.com/wp-content/uploads/2025/06/FINAL_Bicara_ASCO_TiP_Poster-1.pdf)

<a id="topic-3.1.1.3-5"></a>

#### Dose optimization run-in in the annual report

> “As seen below, this registrational trial is designed with a dose selection run-in consistent with the objectives of the FDA’s Project Optimus.”
> “The Phase 2 portion of the FORTIFI-HN01 trial was a dose optimization run-in that randomized patients 1:1:1 to receive either 1500mg QW of ficerafusp alfa in combination with pembrolizumab, 750mg QW of ficerafusp alfa in combination with pembrolizumab, or placebo plus pembrolizumab.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.3-6"></a>

#### FDA dose-optimization guidance on randomized dose comparison

> “A recommended trial design to compare multiple dosages is a randomized, parallel dose-response trial.”
> “When a registration trial contains multiple dosages and a control arm and is designed to establish superior efficacy of one of the dosages compared to the control arm, the trial design should provide strong control of Type I error.”

Source: [FDA (2024)](https://www.fda.gov/media/164555/download)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “Age ≥18 years on the day the Informed Consent Form is signed.”
> “Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.”
> “No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.”
> “Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.”
> “PD-L1 CPS ≥1.”
> “Measurable disease based on RECIST 1.1.”
> “Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”
> “Adequate organ function, as defined in the protocol.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Disease suitable for local therapy administered with curative intent.”
> “Prior treatment with anti-TGFβ therapy.”
> “Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).”
> “Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.”
> “Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.”
> “Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.”
> “Life expectancy less than 3 months.”
> “Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.”
> “Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.”
> “Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.”
> “Active autoimmune disease requiring systemic treatment in the past 2 years.”
> “Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.”
> “Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.”
> “Known history of human immunodeficiency virus (HIV).”
> “Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.”
> “Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.”
> “Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.”
> “Use of a live or live attenuated vaccine within 4 weeks prior to Screening.”
> “Other Inclusion/Exclusion criteria may apply as defined in the protocol.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.4-3"></a>

#### Primary site and histology in the EU trial record

> “Participant has histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: Primary tumor location of paranasal sinuses and nasopharynx, or tumor of any other histology are excluded.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-4"></a>

#### HPV status determination in the EU trial record

> “Participant has documentation of HPV-negative disease per central testing performed if presenting with OPSCC. Tumor tissue from excisional/incisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) must be provided for central testing. Archival tumor tissue is acceptable. A fresh tumor biopsy, using a procedure that is safe for the participant on a lesion not previously irradiated (unless lesion progressed) will be required if tumor tissue is not available. Note: To be eligible to participate in this study, participants with OPSCC must have HPV-negative documentation.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-5"></a>

#### HPV assay developer named in the EU trial record

| Third party | Quoted record |
| --- | --- |
| Organization | “Qiagen Manchester Limited” |
| Duty delegated by the sponsor | “Development of HPV DNA Assay” |

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-6"></a>

#### PD-L1 assay and testing in the EU trial record

> “Participant is eligible to receive pembrolizumab as frontline monotherapy with documented tumor PD-L1 CPS ≥1 (PD-L1 immunohistochemistry [IHC] via 22C3). If appropriate local documentation of PD-L1status is not available, tumor tissue from excisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) must be provided for central testing to determine eligibility.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-7"></a>

#### Prior-therapy criteria in the EU trial record

> “No prior systemic therapy administered in the R or M setting. Systemic therapy completed >6 months prior to signing ICF if given as part of multimodal treatment for locoregionally advanced disease is allowed.”
> “Prior systemic therapy in the R or M setting.”
> “Prior treatment with anti-TGF-β therapy.”
> “Prior therapy with an anti-EGFR antibody.”
> “Prior history of Grade ≥2 intolerance or hypersensitivity reaction.”
> “Prior (neoadjuvant and/or adjuvant) therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.”
> “PD (radiologically or pathologically confirmed) <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-8"></a>

#### Measurable disease, performance status, and age in the EU trial record

> “Participant has measurable disease based on RECIST 1.1 as determined by BICR. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated. Baseline Scan must be transferred to BICR for assessment.”
> “Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”
> “Participant is >18 years of age or of an acceptable age according to local regulations, whichever is older on the day the ICF is signed.”
> “Life expectancy of less than 3 months and/or has rapidly progressing disease in the treating investigator's opinion.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-9"></a>

#### Bleeding risk exclusion in the EU trial record

> “Participants who are at higher risk of bleeding including participants with known bleeding diathesis, or who have current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-10"></a>

#### Central laboratory HPV confirmation in the initial trial-in-progress abstract

> “Eligible patients must have histologically confirmed R/M HNSCC with primary lesions in the oral cavity, larynx, or hypopharynx, or OPSCC, excluding HPV-positive OPSCC confirmed by central laboratory testing.”
> “Additional criteria include no prior systemic therapy for R/M disease, PD-L1 positive tumors (CPS ≥1), measurable disease per RECIST v1.1 assessed by BICR, and ECOG performance status of 0 or 1.”

Source: [Ferrarotto et al. (2025a)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS6113)

<a id="topic-3.1.1.4-11"></a>

#### Central laboratory HPV confirmation in the updated trial-in-progress abstract

> “Eligible patients must have histologically confirmed R/M HNSCC with primary lesions in the oral cavity, larynx, or hypopharynx, or HPV-negative OPSCC confirmed by central laboratory testing.”
> “Additional eligibility criteria include no prior systemic therapy for R/M disease, PD-L1-positive tumor (CPS ≥1), measurable disease per RECIST v1.1, and ECOG performance status 0 or 1.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.4-12"></a>

#### Key eligibility criteria in the updated trial-in-progress poster

> “Eligible primary tumor locations: oral cavity, hypopharynx, larynx, or oropharynx (HPV negative if OPSCC)”
> “No prior systemic therapy for R/M disease, and completed systemic therapy >6 months prior if part of multimodal treatment for locoregionally advanced disease”
> “Prior therapy with an anti-EGFR antibody (except radiosensitizing and multimodal treatment for locoregionally advanced disease)”
> “Prior neoadjuvant and/or adjuvant immune checkpoint inhibitor therapy completed ≤6 months prior to study treatment initiation”
> “Patients at higher risk of bleeding (including known bleeding diathesis), with current active major bleeding, or major bleeding episode ≤4 weeks prior to enrollment”
> “1L R/M HNSCC excluding HPV-positive OPSCC”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-3.1.1.4-13"></a>

#### Population description in the first-enrollment press release

> “FORTIFI-HN01 is a global, randomized, double-blinded, placebo-controlled, pivotal Phase 2/3 trial that aims to enroll approximately 650 R/M HNSCC patients, excluding patients with human papillomavirus (HPV)-positive with oropharyngeal squamous cell carcinoma.”
> “Patients enrolled in the trial must have a PD-L1 CPS greater than or equal to one, and not have received systemic therapy in the R/M setting.”

Source: [Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi)

<a id="topic-3.1.1.4-14"></a>

#### HPV testing by primary site in the annual report

> “An estimated 80% of cases of R/M HNSCC are HPV-negative, with testing for HPV status typically only being conducted in tumors originating from the oropharynx.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Treatment arms in the ClinicalTrials.gov record

| Arm | Quoted regimen |
| --- | --- |
| Phase 2 Arm A | “ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)” |
| Phase 2 Arm B | “ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W” |
| Phase 2 Arm C and Phase 3 Arm C (placebo comparator) | “placebo QW + pembrolizumab 200 mg Q3W” |
| Phase 3 OBD Arm | “ficerafusp alfa OBD + pembrolizumab 200 mg Q3W” |

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.5-2"></a>

#### Route, schedule, and duration in the updated trial-in-progress abstract

> “Patients receive pembrolizumab (200 mg IV every 3 weeks for up to 35 cycles) and either ficerafusp alfa or placebo IV QW until disease progression or unacceptable toxicity.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.5-3"></a>

#### Selected phase 3 dose and phase 2 crossover in the updated trial-in-progress poster

> “The Phase 3 portion is now enrolling with the optimal biological dose of ficerafusp alfa 1500 mg weekly in combination with pembrolizumab”
> “Following the decision on the optimal biologic dose (Phase 2), patients randomized to the 750 mg arm crossed over to the 1500 mg arm.”
> “This study was funded by Bicara Therapeutics Inc. with access to pembrolizumab in collaboration with Merck Sharp & Dohme LLC”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using RECIST v1.1 Objective Response Rate and Overall Survival as the Primary Endpoints

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoints in the ClinicalTrials.gov record

| Primary endpoint | Quoted measure | Quoted definition | Quoted time frame |
| --- | --- | --- | --- |
| Phase 2 safety | “Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.” | “To assess safety and tolerability of ficerafusp alfa with pembrolizumab.” | “Up to 30 days post end of treatment for TEAEs (90 days for SAEs).” |
| Phase 2 response | “Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)” | “ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.” | “Approximately 1 year.” |
| Phase 3 response | “Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.” | “ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.” | “Approximately 2 years.” |
| Phase 3 survival | “Phase 3 - Overall Survival (OS)” | “OS: Defined as the time from the randomization to death due to any cause.” | “Approximately 3 years.” |

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary endpoints in the EU trial record

> “Phase 2 (Dose Selection) - ORR is defined as the proportion of participants in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.”
> “Phase 3 - OS: Defined as the time from the randomization to death due to any cause.”
> “Phase 3 - ORR: Defined as the proportion of the partcipants in the FAS who have confirmed CR or PR by BICR per RECIST 1.1. (Subset of FAS).”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.6.1-3"></a>

##### Secondary endpoints in the ClinicalTrials.gov record

> “Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.”
> “Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.”
> “Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.”
> “ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).”
> “Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.”
> “Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.”
> “Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.”
> “Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.”
> “Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.6.1-4"></a>

##### Patient-reported outcome endpoints in the ClinicalTrials.gov record

> “TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score.”
> “Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.6.1-5"></a>

##### Endpoint roles and tumor assessment schedule in the updated trial-in-progress abstract

> “The primary endpoints are objective response rate (ORR) per RECIST v1.1 (blind independent committee review) and overall survival.”
> “Tumor imaging occurs every 6 weeks during the first year and every 9 weeks thereafter.”
> “Secondary endpoints include safety, duration of response, progression free survival, clinical benefit rate, and patient-reported outcomes.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.6.1-6"></a>

##### Endpoint roles in the updated trial-in-progress poster

> “Phase 2: Safety and efficacy of the two doses to support selection of optimal biological dose”
> “Phase 3: ORR (interim analysis) and OS (final analysis)”
> “Exploratory endpoint”
> “Biomarker evaluation”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-3.1.1.6.1-7"></a>

##### Regulatory basis for the response and survival endpoints in the annual report

> “As a result of our discussions with the FDA, we believe that ficerafusp alfa has a path to accelerated approval using an ORR-based interim endpoint with confirmatory approval based on an OS endpoint.”
> “We believe the trial can support an accelerated approval on the basis of overall response rate, or ORR, six-month durability, and qualitative OS.”
> “Product candidates studied for their safety and effectiveness in treating serious conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.6.1-8"></a>

##### Regulatory basis in the first-enrollment press release

> “The primary endpoints are overall response rate based on RECIST v1.1 and overall survival, with results potentially supporting filings for both accelerated approval and full approval. Secondary endpoints include progression free survival and duration of response.”

Source: [Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi)

<a id="topic-3.1.1.6.1-9"></a>

##### FDA endpoint guidance on objective response rate and overall survival

> “While durable ORR has been used as a traditional approval endpoint in some circumstances, ORR has also been the most commonly used surrogate endpoint in support of accelerated approval.”
> “Tumor response is widely accepted by oncologists in guiding cancer treatments.”
> “Survival is considered the most reliable cancer endpoint, and when studies can be conducted to adequately assess survival, it is usually the preferred endpoint.”
> “Overall survival should be evaluated in randomized controlled studies.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-10"></a>

##### FDA draft guidance on one randomized trial for accelerated approval and verification of benefit

> “Alternatively, sponsors could design a single randomized controlled trial to support accelerated approval, that is also powered for the longer-term clinical endpoint with follow-up in the same trial to verify clinical benefit (i.e., “one-trial” approach).”

Source: [FDA (2023)](https://www.fda.gov/media/166431/download)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 650”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned enrollment and power in the annual report

> “The total trial will enroll approximately 650 patients, which we believe is sufficiently powered to achieve results that may lead to regulatory approval.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.7.1-3"></a>

##### Planned enrollment in the updated trial-in-progress abstract

> “The trial is actively recruiting, with planned enrollment of ~650 subjects.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.7.1-4"></a>

##### Planned enrollment in the updated trial-in-progress poster

> “It is planned that about 650 people will take part in this trial.”
> “Two out of every three participants also receive ficerafusp alfa, and one out of every three participants also receive a placebo”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Response analysis sets in the ClinicalTrials.gov record

> “ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.”
> “ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.7.2-2"></a>

##### Response analysis set in the EU trial record

> “Phase 3 - ORR: Defined as the proportion of the partcipants in the FAS who have confirmed CR or PR by BICR per RECIST 1.1. (Subset of FAS).”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.7.2-3"></a>

##### Phase 2 participants contributing to the primary analyses in the annual report

> “Importantly, our Phase 2/3 FORTIFI-HN01 trial design enables the patients enrolled in the 1500mg QW treatment arm during dose selection to contribute to the primary analyses of the FORTIFI-HN01 pivotal trial, while those enrolled in the 750mg QW treatment arm will not (but will have the option to roll over to the 1500mg QW dose).”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.7.2-4"></a>

##### Interim and final analyses in the trial-in-progress materials

> “An interim analysis evaluating ORR is planned.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

> “Phase 3: Dual primary endpoints”
> “ORR (interim analysis)”
> “OS (final analysis)”

Source: [Ferrarotto et al. (2025b)](https://www.bicara.com/wp-content/uploads/2025/06/FINAL_Bicara_ASCO_TiP_Poster-1.pdf)

<a id="topic-3.1.1.7.2-5"></a>

##### Interim analysis timing in the third-quarter results press release

> “Achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in first-line (1L) recurrent or metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), to enable topline results from an interim analysis in mid-2027.”

Source: [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### First enrollment in the press release

> “today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)”

Source: [Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi)

<a id="topic-3.1.1.8.1-2"></a>

##### Completion of phase 2 and transition to phase 3 in the annual report

> “In January 2026, we announced that 1500mg QW of ficerafusp alfa was selected as the optimal dose to bring forward in the Phase 3 portion of the FORTIFI-HN01 trial. In February 2026, the transition to the Phase 3 portion of the FORTIFI-HN01 trial was completed.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.8.1-3"></a>

##### Phase 2 arm disposition in the updated trial-in-progress poster

> “750 mg arm discontinued”
> “The Phase 2 portion is complete”
> “Following the decision on the optimal biologic dose (Phase 2), patients randomized to the 750 mg arm crossed over to the 1500 mg arm.”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-3.1.1.8.1-4"></a>

##### Enrollment status in the quarterly report

> “In November 2026, we announced that FORTIFI-HN01 reached substantial enrollment to enable an interim analysis in mid-2027 to support a potential approval and U.S. launch in 2028.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Phase 2 dose selection outcome in the press release

> “Selected 1500 mg QW of ficerafusp alfa in combination with pembrolizumab as the optimal dose for Phase 3 FORTIFI-HN01 pivotal study, earlier than anticipated”
> “Bicara has aligned with the U.S. Food and Drug Administration (FDA) on a clear path to implement, by the end of the first quarter, the optimal dose for Phase 3 of FORTIFI-HN01, a global, randomized, double-blind, placebo-controlled, pivotal trial of ficerafusp alfa in combination with pembrolizumab in first-line (1L) human papillomavirus (HPV)-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).”

Source: [Bicara Therapeutics phase 3 dose and 2026 outlook announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides)

<a id="topic-3.1.1.8.3-2"></a>

##### Data informing dose selection in the annual report

> “The dose determination was informed by the open-label data sets from our Phase 1/1b trial, as well as data from the treatment arms of the Phase 2 portion of the FORTIFI-HN01 trial.”
> “These data supported the selection of 1500mg QW of ficerafusp alfa as the optimal dose to advance into the Phase 3 portion of our FORTIFI-HN01 pivotal trial.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.8.3-3"></a>

##### Biomarker basis for dose selection in the full-year results press release

> “Biomarker analyses demonstrated that the 1500mg dose achieved greater TGF-β inhibition, stronger immune activation, and deeper clinical responses, supporting higher dose selection and further derisking the ORR interim analysis for the FORTIFI-HN01 pivotal study.”

Source: [Bicara Therapeutics fourth quarter and full year 2025 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-fourth-quarter-and-full-year-2025)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

FORTIFI-HN01 has reported no efficacy, safety, or baseline results; the phase 3 dose selection rests on company statements that it was informed by the open-label phase 1/1b data sets and by data from the phase 2 treatment arms. Accelerated approval would rest on an interim ORR analysis, with clinical benefit verified by OS in the same trial, the design FDA draft guidance calls the “one-trial” approach; FDA draft guidance states that preserving trial integrity is critical to that approach, and Bicara states that “interim and preliminary data may not be predictive of final results” and that confirmatory studies may not show clinical benefit. The control arm is placebo plus pembrolizumab 200 mg every 3 weeks, and participants treated at 1500 mg weekly in phase 2 contribute to the primary analyses while those treated at 750 mg weekly do not.

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990); [FDA (2023)](https://www.fda.gov/media/166431/download); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-3.1.1.9-2"></a>

#### Verification of clinical benefit after accelerated approval in the annual report

> “Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.9-3"></a>

#### Interim data in the quarterly report

> “As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-3.1.1.9-4"></a>

#### Potential bias in a single-trial accelerated approval design in FDA draft guidance

> “Preserving the integrity of the trial is critical in assessing the feasibility and appropriateness of the “one-trial” approach because the evaluation of the data and subsequent regulatory action on an accelerated approval application may inadvertently introduce bias.”

Source: [FDA (2023)](https://www.fda.gov/media/166431/download)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
